Huadong Medicine

Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets

Retrieved on: 
수요일, 9월 8, 2021

SHANGHAI, Sept. 8, 2021 /PRNewswire/ --Huadong Medicine (SZ.000963) and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the companies have entered into a co-development partnership to accelerate the discovery of breakthrough small-molecule therapeutics by leveraging an innovative approach to oncology.

Key Points: 
  • SHANGHAI, Sept. 8, 2021 /PRNewswire/ --Huadong Medicine (SZ.000963) and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the companies have entered into a co-development partnership to accelerate the discovery of breakthrough small-molecule therapeutics by leveraging an innovative approach to oncology.
  • Pursuant to the collaboration agreement, Insilico and Huadong Medicine will launch a new drug discovery project involving the research and development (R&D) teams of both parties.
  • The project team will interfere with protein-protein interactions to hit undruggable targets that regulate tumor growth.
  • In addition, Huadong Medicine's R&D organization currently has more than 1000 FTEs involved in drug discovery, preclinical research, clinical research, CMC, and RA.

HC2 Holdings Portfolio Company R2 Technologies Receives Final Tranche of $30 Million Investment

Retrieved on: 
수요일, 2월 3, 2021
HC2 Holdings, Huadong Medicine

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (HC2 or the Company) (NYSE: HCHC) today announced that R2 Technologies Inc. ("R2"), founded by HC2s portfolio company Pansend Life Sciences (Pansend), has received $10 million in funding from Huadong Medicine Company Limited (Huadong), a leading publicly traded Chinese pharmaceutical company.

Key Points: 
  • NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (HC2 or the Company) (NYSE: HCHC) today announced that R2 Technologies Inc. ("R2"), founded by HC2s portfolio company Pansend Life Sciences (Pansend), has received $10 million in funding from Huadong Medicine Company Limited (Huadong), a leading publicly traded Chinese pharmaceutical company.
  • Huadongs investment will be used to fund the launch of R2 Technologies first-to-market innovations Glacial Rx and Glacial Spa.
  • In exchange for its equity investment in R2, Huadong receives exclusive distribution rights for R2s products in the China and selected Asia-Pacific markets.
  • This investment constitutes the third and final tranche of Huadongs $30 million equity investment at a predetermined post-money valuation of $113 million for R2, established at the time of R2s Series B close in June 2019.

China Pharmaceutical Distribution Industry Report to 2026 - ResearchAndMarkets.com

Retrieved on: 
목요일, 5월 28, 2020
Health, Pharmaceutical, Health, Economy of China, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Huadong Medicine, Guangzhou Pharmaceuticals, Pharmaceutical industry, China National Pharmaceutical Group, Simcere Pharmaceutical

The "China Pharmaceutical Distribution Industry Report, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Pharmaceutical Distribution Industry Report, 2019-2026" report has been added to ResearchAndMarkets.com's offering.
  • Western medicine sales dominate pharmaceutical distribution in China, accounting for 72.2% in 2018 the sales in East China and Central South China seize larger shares up to 62.1% together in 2018.
  • A competition pattern has been developed in the country where there are national pharmaceutical distributors represented by China National Pharmaceutical Group Corporation (Sinopharm), China Resources Pharmaceutical Commercial Group, Shanghai Pharmaceuticals and Jointown Pharmaceutical Group and the regional ones represented by NanJing Pharmaceutical, Guangzhou Pharmaceuticals, Chongqing Pharmaceutical, Huadong Medicine, Sichuan Kelun, Zhejiang Int'l, Realcan Pharmaceutical, Guangxi Liuzhou Pharmaceutical Co., Ltd. and Luyan Pharma Co., Ltd.
  • Pharmaceutical distribution industry in China (development environment, status quo, market size/structure, competitive landscape, development trends, etc.)

China Pharmaceutical Distribution Industry Report, 2019-2026

Retrieved on: 
월요일, 5월 4, 2020
Health, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Huadong Medicine, Guangzhou Pharmaceuticals, Pharmaceutical industry in India, Pharmaceutical companies, Taiho Pharmaceutical

Western medicine sales dominate pharmaceutical distribution in China, accounting for 72.2% in 2018; the sales in East China and Central South China seize larger shares up to 62.1% together in 2018.

Key Points: 
  • Western medicine sales dominate pharmaceutical distribution in China, accounting for 72.2% in 2018; the sales in East China and Central South China seize larger shares up to 62.1% together in 2018.
  • A competition pattern has been developed in the country where there are national pharmaceutical distributors represented by China National Pharmaceutical Group Corporation (Sinopharm), China Resources Pharmaceutical Commercial Group, Shanghai Pharmaceuticals and Jointown Pharmaceutical Group and the regional ones represented by NanJing Pharmaceutical, Guangzhou Pharmaceuticals, Chongqing Pharmaceutical, Huadong Medicine, Sichuan Kelun, Zhejiang Int'l, Realcan Pharmaceutical, Guangxi Liuzhou Pharmaceutical Co., Ltd. and Luyan Pharma Co., Ltd.
    As of end of November 2018, there had been 13,598 pharmaceutical wholesalers nationwide which competed fiercely in the scattered market.
  • Huge potentials of the pharmaceutical distribution industry has lured investors and frequent M&As occurred over the recent years.
  • Pharmaceutical distribution industry in China (development environment, status quo, market size/structure, competitive landscape, development trends, etc.